Universal Health Services (UHS)
(Real Time Quote from BATS)
$165.85 USD
+0.75 (0.45%)
Updated Apr 26, 2024 03:50 PM ET
2-Buy of 5 2
A Value B Growth F Momentum A VGM
Price, Consensus and EPS Surprise
UHS 165.85 +0.75(0.45%)
Will UHS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for UHS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UHS
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
Centene (CNC) Q1 Earnings Beat on Premiums, '24 EPS View Hiked
UHS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Value Investors Buy Universal Health Services (UHS) Stock?
Universal Health (UHS) Q1 Earnings Beat on Rising Patient Days
Compared to Estimates, Universal Health Services (UHS) Q1 Earnings: A Look at Key Metrics
Other News for UHS
Universal Health price target raised by $8 at Barclays, here's why
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)
Barclays Remains a Hold on Universal Health (UHS)
Universal Health’s Strong Q1 Performance and Upbeat Financial Outlook Justify Buy Rating
Universal Health Surpasses Q1 Expectations with Strong Behavioral Segment Performance and Solid Growth Trajectory: A Buy Rating Justified